Sponsor or institution
Clinical trials and research at Groupe Francophone des Myelodysplasies
As of November 12, 2026, Find a Trial lists 4 clinical trials run by Groupe Francophone des Myelodysplasies that are recruiting, at sites in 2 countries (most in France (4), Italy (1)). By phase: Phase 1 (1), Phase 1/2 (1), Phase 2 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 4Clinical trials
- 2Countries
Newest trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Momelotinib treatment for VEXAS syndrome | Phase 2 | Angers and 10 other locations | Recruiting | Aug 1, 2025 |
| Registry for patients with myelodysplastic syndromes and therapy-related acute myeloid leukemia | — | Rouen | Recruiting | May 4, 2025 |
| Oral arsenic treatment for low-risk myelodysplastic syndromes | Phase 1 | Nice and 2 other locations | Recruiting | Nov 1, 2024 |
| Combining Luspatercept with ESA for Low-Risk Myelodysplastic Syndromes | Phase 1/2 | Amiens and 40 other locations | Recruiting | Jan 6, 2022 |
All recruiting trials (4)
-
Momelotinib treatment for VEXAS syndrome
This trial will test whether the oral drug momelotinib helps adults with VEXAS syndrome (with or without myelodysplastic syndrome) who need daily steroids to control inflammation.
-
Registry for patients with myelodysplastic syndromes and therapy-related acute myeloid leukemia
This study is collecting health information from adults with myelodysplastic syndromes and therapy-related acute myeloid leukemia to better understand these conditions and improve patient care.
-
Oral arsenic treatment for low-risk myelodysplastic syndromes
This phase I test will see if a short-course oral arsenic regimen is safe and can help blood counts in adults with low-risk MDS who failed or are ineligible for ESAs or luspatercept.
-
Combining Luspatercept with ESA for Low-Risk Myelodysplastic Syndromes
This study is testing if combining a new drug called luspatercept with existing treatments can help people with low-risk myelodysplastic syndromes who haven't responded to current therapies.
Quick answers
How many clinical trials run by Groupe Francophone des Myelodysplasies are recruiting right now?
4, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 2 countries. The most sites are in France (4 trials), Italy (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1: 1, Phase 1/2: 1, Phase 2: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.